News

PipelineReview.com18h
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
SOUTH SAN FRANCISCO, CA, USA I May 6, 2025 I IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and ...
PipelineReview.com18h
Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company
New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism ...
PipelineReview.com18h
AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis
Company is advancing a new class of immunomodulators for autoimmune and inflammatory disorders with high unmet medical need- ...
PipelineReview.com18h
Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy
INGELHEIM, Germany I May 6, 2025 I Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the ...